N/A N=1,360 Health-E You: Reducing Unintended Pregnancies Among Hispanic Adolescents
Unprotected Sex · Unsafe Sex
Primary: Contraception Use Self-efficacy Scale Score (Aim 1b) — 23.2; 22.45; 25.22; 23.04 Scores on a scale — p=0.011
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Resting-State Neural Connectivity in Patients With Subjective Tinnitus Without Bother
Tinnitus
Primary: Number of Participants With Changes in Blood Oxygen Level as Measured by Functional Connectivity MRI — 18 participants — p=<0.01
Phase 4 N=5 Shoulder Contraceptive Implant Study
Contraception
Primary: Pharmacokinetics in the Form of Serum Etonogestrel Concentrations — 511.7; 136.6 pg/mL
Phase 4 N=109 Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
Bleeding · Implants · Breakthrough Bleeding
Primary: Total Number of Consecutive Bleeding-free Days in First 30 Days From Day 1 of First Treatment (TX1) — 18.5; 8.7 days
N/A N=1,919 Evaluation of Participant Responses to Educational Counseling About Different Combined Hormonal Contraceptive Choices (P06557)
Contraception
Primary: Number of Participants Choosing Each Hormonal Contraceptive Method Before and After Counseling — 1207; 1199; 60; 131 Participants — p=0.705
N/A N=88 Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant
Etonogestrel Contraceptive Implant, Bothersome Bleeding
Primary: Impact of Aygestin (and Dose of Aygestin) on the Management of Bothersome Bleeding Associated With the Etonogestrel Contraceptive Implant — 2.73; 2.77; 2.76; 2.27 units…
N/A N=40 Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®
Pharmacokinetics
Primary: Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol — 1275; 1240; 21.9; 14.8 ng/L
N/A N=786 Patient-Centered Support for Contraceptive Decision-Making
Contraception · Contraceptive Behavior
Primary: Contraceptive Continuation — 201; 174; 154; 118 Participants — p=0.46
Early Phase 1 N=40 Ovarian Function With ENG Implant and UPA Use
Contraception
Primary: Number of Participants With Ovulation With Implant-alone — 7; 0 Participants
Phase 4 N=69 Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant
Complications; Contraceptive · Female Lactation
Primary: Time to Lactogenesis Stage II — 64.3; 65.2 hours — p=<0.05
Phase 3 N=65 Intervention to End Recurrent Unscheduled Bleeding Trial
Contraception · Bleeding
Primary: Number of Bleeding/Spotting Days With Use of Ulipristal Acetate as Measured by Daily Bleeding Diaries — 7; 12 days — p=0.002
Phase 4 N=150 Breastfeeding Etonogestrel Implant Study
Contraception
Primary: Number of Participants With Continuation of Breastfeeding at 8 Weeks Postpartum — 54; 45; 48; 43 Participants
Phase 3 N=81 Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents
Contraceptive Usage
Primary: Number of Participants With Contraceptive Implant Continuation at Six Months Postpartum — 15; 7 Participants
Phase 4 N=21 Prophylaxis Regimen for Hemophilia A Patients
Hemophilia A · Prophylaxis of Bleeding
Primary: Overall Number of Participants With Favorable Outcome on the Score-assigned Prophylaxis Regimen — 12 participants
N/A N=22 Peri-Implant Healing Around Two Different Machined-Collar Designs After 25 Years of Function
Jaw, Edentulous
Primary: Comparison of Distance Between First Bone to Implant Contact Point (fBIC) and Microgap (MG), After 25 Years of Function, Between All B, All SW, and All SC Dental Implant…